AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
📈 **POSITIVE** • Low confidence analysis (52%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (82%) **Content type:** General